Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.08)
# 2,801
Out of 4,851 analysts
107
Total ratings
41.82%
Success rate
-6.37%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $7.06 | -0.85% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $179.16 | +11.63% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $173.59 | +3.69% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $4.04 | -0.99% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $4.63 | +223.97% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $714.88 | -5.58% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $63.59 | +2.22% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.23 | +6.86% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $250.51 | +5.78% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $15.89 | +25.87% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $140 | $155.48 | -9.96% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $39.78 | -9.50% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $142.78 | +85.60% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $53.51 | -15.90% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $2.27 | +76.21% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $18.73 | +22.80% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $22.97 | -12.93% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.95 | +341.18% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.37 | +243.25% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.30 | +378.26% | 2 | Jan 4, 2022 |
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $7.06
Upside: -0.85%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $179.16
Upside: +11.63%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $173.59
Upside: +3.69%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $4.04
Upside: -0.99%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $4.63
Upside: +223.97%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $714.88
Upside: -5.58%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $63.59
Upside: +2.22%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.23
Upside: +6.86%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $250.51
Upside: +5.78%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.89
Upside: +25.87%
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $155.48
Upside: -9.96%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $39.78
Upside: -9.50%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $142.78
Upside: +85.60%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $53.51
Upside: -15.90%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $2.27
Upside: +76.21%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $18.73
Upside: +22.80%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $22.97
Upside: -12.93%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.95
Upside: +341.18%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.37
Upside: +243.25%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.30
Upside: +378.26%